Feb 17, 2026
•
7 min read
Gazyva first-ever PMN win • OCUL faces make-or-break readout today • India's $240M reshoring play.
Feb 16, 2026
8 min read
Surrogate scrutiny intensifies • Oral achondroplasia data raises switching pressure • Lilly builds $1.5B ahead of PDUFA.
Feb 13, 2026
Oral dwarfism pill outpaces prior injectable data • Hormone boxed warnings removed • Seres & Ultragenyx cut staff
Feb 12, 2026
10 min read
First immunotherapy for platinum-resistant ovarian cancer, Viking confirms Phase 3 timeline, Healthcare adds 82k jobs.
FDA cites comparator design in flu filing • Hunter syndrome application declined • CSL leadership transition
China-sourced drug development, AI-enabled discovery, FDA telehealth extension, and Krystal Biotech RMAT.
Roivant subsidiary posts rare autoimmune win, Gene therapy decision under FDA review, IPO volatility tests 2026 window
FDA grants enforcement discretion for natural colors. Plus: manufacturers join federal DTC pricing framework; Cardinal Health updates FY26 outlook.
Rare disease incentives restored, Medtronic acquires CathWorks, Eikon prices at $18.
Federal strategy shifts from mRNA to oral antivirals • Monthly GLP-1 hits 10–12% vs. 15%+ bar • Quest MRD disrupts bone marrow biopsies
PreCheck applications now open. Venglustat wins Gaucher, misses Fabry.
Originating site restrictions return. AZ pays $1.2B upfront for monthly obesity dosing platform.
Stay on the Cutting Edge of Biotech, MedTech, and Pharma.
